Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.

导出 OA

翻译打印收藏纠错

作者： Rasmus,Goll ^[1] ; Øystein K,Moe ^[2] ; Kay-Martin,Johnsen ^[3] ; Renate,Meyer ^[4] ; Joachim,Friestad ^[1] ; Mona D,Gundersen ^[2] ; Hege,Kileng ^[2] ; Knut,Johnsen ^[5] ; Jon R,Florholmen ^[1]

作者单位： Research Group of Gastroenterology and Nutrition, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway. ^[1] Department of Gastroenterology, Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway. ^[2] Research Group of Gastroenterology and Nutrition, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway. Oystein.Kittel.Moe@unn.no. ^[3] Department of Gastroenterology, Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway. Oystein.Kittel.Moe@unn.no. ^[4] Department Internal Medicine, Vestre Viken Hospital, Hønefoss, Norway. ^[5] Department Internal Medicine, Hammerfest Hospital Hammerfest, Tromsø, Norway. ^[6]

关键词 Anti-TNF therapy Biological therapy Crohn’s disease Inflammatory bowel disease Interleukin 17 Interleukin 23 Tumor necrosis factor Ulcerative colitis Ustekinumab Vedolizumab

主题词人类(Humans);慢性病(Chronic Disease);结肠炎, 溃疡性(Colitis, Ulcerative);Crohn病(Crohn Disease);炎性肠疾病(Inflammatory Bowel Diseases);肿瘤坏死因子α(Tumor Necrosis Factor-alpha)

DOI 10.1186/s12876-022-02559-5

PMID 36384462

发布时间 2022-11-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交